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bstract
A novel, simple, economical reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed for
uantifying clopidogrel in bulk and tablet form with greater precision and accuracy. Separation was achieved on a Develosil ODS
G-5 RP C18 (15 cm ×  4.6 mm, i.d. 5 m) column in isocratic mode with a mobile phase consisting of acetonitrile:phosphate (65:35)
uffer (pH 2.85) with a flow rate of 1 mL/min. Detection was carried out at 225 nm. The retention time of clopidogrel was 7.48 min.
he method was validated as per the guidelines of the International Conference on Harmonisation of Technical Requirements for
egistration of Pharmaceuticals for Human Use (ICH). Linearity was established for clopidogrel in the range 10–60 g/mL, with an
2 value of 0.999. The recovery of clopidogrel was 99.71–100.03%. The high recovery and low relative standard deviation confirm
he suitability of the proposed method for estimating the concentrations of the drug in bulk and tablet dosage forms. Validation
tudies demonstrated that the proposed RP-HPLC method is simple, specific, rapid, reliable and reproducible for the determination
f clopidogrel for quality control.
 2014 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
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Clopidogrel bisulfate was officially registered in
the United States Pharmacopeia in 2007. Its chemical
name is (+)--(2-chlorophenyl)-6,7-dihydrothieno[3,2-
c]pyridine-5(4H)-acetic acid methyl ester sulfate. It
inhibits adenosine diphosphate (ADP)-induced platelet
aggregation (Fig. 1) and acts by direct inhibition of ADP
binding to its receptor and of subsequent ADP-mediated
activation of the glycoprotein GPIIb/IIIa complex. It is
used effectively to reduce the incidence of ischaemic
strokes, heart attacks and claudication due to vascular
diseases such as atherosclerosis [1]. A literature sur-
vey revealed various assays for determining clopidogrel
in pharmaceutical dosage forms, including chemometry
[2], spectrophotometry [3], thin-layer chromatogra-
phy [4], high-performance thin-layer chromatography
332 N.K. Sahoo et al. / Journal of Taibah UniveFig. 1. Chemical structure of clopidogrel.
[5,6], high-performance liquid chromatography (HPLC)
[6–15], liquid chromatography–mass spectrometry [16]
and voltammetry [17].
Analysis of the carboxylic acid metabolite of clopid-
ogrel in plasma and serum has been reported with HPLC
[17,18], liquid chromatography–tandem mass spectrom-
etry [19] and gas chromatography–mass spectrometry
[20]. The aim of the present work was to develop and
validate a sensitive reverse-phase (RP)-HPLC method
for estimating the concentration of clopidogrel in bulk
and in tablet dosage forms.
2.  Experimental
2.1.  Materials
Pure clopidogrel, used as a working standard, was
obtained from Aurobindo Pharma, Hyderabad, India.
Tablets containing clopidogrel (Clopilet® and Plavix®)
were obtained from Apollo Pharmaceuticals Pvt. Ltd.,
Visakhapatnam, India, and used within their shelf life.
Acetonitrile and water (HPLC grade) were purchased
from Merck, India. All other chemicals and reagents
employed were of analytical grade and purchased from
Desai Chemicals, Visakhapatnam, India.
2.2.  Instrumentation
The chromatographic system used was an Analyti-
cal Technologies Ltd UV 2230 UV-Vis detector. Data
were integrated with A-4000 version software. Sam-
ples were injected into a Develosil ODS HG-5 RP
C18 (15 cm ×  4.6 mm, i.d. 5 m) column. An Analytical
Technologies Ltd. sonicator was used to enhance disso-
lution of the compounds. A Wenster digital pH meter
was used to adjust the pH.
2.3.  Chromatographic  conditions
The HPLC system used was operated isocratically,
◦with the column temperature maintained at 30 C and
a mobile phase composed of acetonitrile:phosphate
(65:35, v/v) buffer (pH adjusted to 2.85 with o-
phosphoric acid) at a flow rate of 1.0 mL/min and arsity for Science 8 (2014) 331–336
run time of 10 min. Before use, the mobile phase was
degassed in an ultrasonic bath and filtered through a
Millipore vacuum filter system equipped with a 0.45-
m vacuum filter. The drug was detected and quantified
at 225 nm.
2.4.  Preparation  of  standard  solutions
The stock solution was prepared by transferring
100 mg of clopidogrel into a 100-mL volumetric flask, to
which a small amount of diluent was added; the mixture
was sonicated to dissolution and made up to volume with
the mobile phase. Final concentrations of 10–60 g/mL
were prepared from the stock solution for calibration of
the standard curve.
2.5.  Assay  of  clopidogrel  in  marketed  tablets
Twenty tablets of each marketed formulation were
accurately weighed and crushed to a fine powder in a
mortar. Then, 100 mg of the powder were transferred
into a 100-mL volumetric flask, to which 25 mL of dilu-
ent were added, followed by 10 mL of o-phosphoric acid.
The mixture was sonicated to dissolve the excipients and
then made up to volume with mobile phase. After 15 min
of mechanical shaking, the solution was maintained in
an ultrasonic bath for 15 min and then filtered through
0.45-m filter paper. Suitable aliquots of the filtered
solution were transferred to a volumetric flask and made
up to volume with mobile phase (40 g/mL) to yield six
concentrations of clopidogrel. A 20-L volume of the
sample solution was injected into the chromatographic
system six times under optimized chromatographic con-
ditions. The peak areas were measured at 225 nm, and
the concentrations in the samples were determined by
interpolation from previously obtained calibration plots
for each drug.
3.  Method  validation
The method was validated in accordance with the
guidelines of the International Conference on Harmo-
nisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) [14]. The param-
eters assessed were linearity, accuracy, limit of detection
(LOD), limit of quantification (LOQ), precision, repro-
ducibility, robustness and system suitability.3.1.  Accuracy
Accuracy was best determined by the standard addi-
tion method. Samples of clopidogrel previously analyzed
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4.4.  Precision:  intra-assay  and  inter-assay
The intra- and inter-day variation of the method
was measured. The high mean values and the lowN.K. Sahoo et al. / Journal of Taiba
or active pharmaceutical ingredient (API) were added
ith standard drug solutions and analyzed by the pro-
osed method. Recovery (%), relative standard deviation
RSD) (%) and bias (%) were calculated for each con-
entration [21].
.2.  Precision
Precision was determined as both repeatability
nd intermediate precision, in accordance with ICH
uidelines. The repeatability of sample injection was
etermined as intra-day and intermediate variation. For
hese determinations, a single concentration (40 g/mL)
f clopidogrel API was tested at different intervals and
n different days.
.3.  Robustness
The concept of the robustness of an analytical pro-
edure has been defined by the ICH as “a measure of
ts capacity to remain unaffected by small but delib-
rate variations in method parameters”. To determine
he robustness of the method, experimental conditions
re purposely altered, and chromatographic character-
stics are evaluated. The influence of small changes
n chromatographic conditions, such as in flow rate
±0.1 mL/min), the wavelength for detection (±2 nm)
nd acetonitrile content in the mobile phase (±2%), were
tudied to determine the robustness of the method.
.4.  Limit  of  detection  and  limit  of  quantiﬁcation
The LOD of an analytical method may be defined as
he concentration that gives rise to an instrument sig-
al that is significantly different from the blank. The
OQ is the concentration that can be quantified reliably
ith a specified level of accuracy and precision and rep-
esents the concentration of analyte that would yield a
ignal:noise ratio of 10 [21].
.  Results  and  discussion
.1.  Optimization  of  chromatographic  conditions
The chromatographic conditions were optimized by
sing different columns, different mobile phases, dif-
erent flow rates, different detection wavelengths and
ifferent diluents for standard drug and marketed tablets,
s summarized in Table 1. The chromatograms obtained
re shown in Figs. 3–5.Concentraon (μg/mL)
Fig. 2. Calibration curve for clopidogrel.
4.2.  Linearity  and  range
The calibration curve (Fig. 2) showed good linearity
in the range 10–60 g/mL for clopidogrel API, with a
correlation coefficient (r2) of 0.999. A typical calibra-
tion curve for clopidogrel fitted the regression equation
y = 53754x  − 24978.
4.3.  Accuracy:  recovery  study
The recovery of the method, determined by adding
a previously analyzed test solution with additional
drug standard solution at three concentrations, was
99.71–100.03%. The values for recovery, RSD and bias
listed in Table 2 indicate that the method is accurate and
better than all previous methods reported [6–15].Fig. 3. RP-HPLC chromatogram of clopidogrel standard drug.
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Table 1
Results of optimization of the method.
Column Mobile phase Flow rate
(mL/min)
Wavelength
(nm)
Observation Result
Microbondapak C18, 5 m,
50 mm × 4.6 mm
Methanol only 0.5 254 No peak Method rejected
Phenomenex reverse-phase C18,
Luna 5 m, 250 mm × 4.6 mm
Acetonitrile only 0.8 254 Resolution 1.0 but not
satisfactory
Method rejected
Microbondapak C18, 5 m,
50 mm × 4.6 mm
Acetonitrile:phosphate
(70:30) buffer (pH 7.8)
1 270 Poor resolution (1.2) Method rejected
Phenomenex reverse-phase C18,
Luna 5 m, 250 mm × 4.6 mm
Acetronitrile:phosphate
(60:40) buffer (pH 5.0)
1 270 Poor resolution (1.1) Method rejected
Develosil ODS HG-5 reverse-phase
C18, 5 m, 15 cm × 4.6 mm
Acetonitrile:phosphate
(65:35) buffer (pH 2.85)
1 225 Good resolution (2.3)
and sharp peak
Method accepted
Table 2
Recovery of the method.
Amount of drug added
(g) to analyte
Recovery from formulation
Mean amount (g) (n = 6) Mean recovery (%) RSD (%) Bias (%)
16 15.95 99.71 0.36 −0.31
showed a clopidogrel content of 100.00% and 99.96%,
respectively (Figs. 4 and 5).20 20.07 
24 23.99 
standard deviation and RSD (<2%) show that the pro-
posed method is precise (Table 3).
4.5.  Robustness
The influence of small changes in chromatographic
conditions, such as flow rate (±0.1 mL/min), wavelength
of detection (±2 nm) and acetonitrile content in the
mobile phase (±2%) (Table 4; RSD < 2%), show the
robustness of the method for the analysis of Clopidogrel
API.
4.6.  LOD  and  LOQThe minimum concentrations at which the analyte
can be reliable detected (LOD) and quantified (LOQ)
Table 3
Intra- and inter-assay variation.
Observed concentration of clopidogrel (g/mL)
Intra-day Inter-day
Time Mean (n = 6) RSD (%) Day Mean (n = 6) RSD (%)
09 : 00 40.01 0.06 1 40.03 0.06
13 : 00 39.99 0.06 2 40.02 0.06
17 : 00 40.02 0.06 3 40.03 0.06100.03 0.08 0.03
99.99 0.01 −0.04
were 0.0003 and 0.001 g/mL, respectively, which are
lower than those found with previously reported methods
[6–15], indicating an advantage of our method.
4.7.  Assays  of  clopidogrel  in  tablet  form
The results of assays performed according to the
regression equation (y  = 53754x  −  24978, r2 = 0.999)
obtained from the standard curve of clopidogrel API are
shown in Table 5. Assay of Clopilet® and Plavix® tabletsTable 4
Robustness of proposed assay.
Change in parameter RSD (%) (n = 6)
Flow (mL/min)
0.9 0.11
1.1 0.06
Detection wavelength (nm)
227 0.09
223 0.22
Acetonitrile:phosphate buffer
67:33 0.09
63:37 0.06
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Table 5
Assay of clopidogrel tablets.
Formulation Labelled
amount (mg)
Amount found
(mg)
Assay ± RSD
(%)
Clopilet® 75 75 75.01 100.004 ± 0.03
Plavix® 300 300 299.88 99.96 ± 0.06
Fig. 4. RP-HPLC chromatogram of Clopilet® 75 tablet.
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[Fig. 5. RP-HPLC chromatogram of Plavix® 300 tablet.
.  Conclusion
A new RP-HPLC method for the assay of clopidogrel
n bulk and in pharmaceutical dosage forms is reported.
he method is simple, reliable, linear, accurate, sensitive
nd reproducible as well as cost-effective for quantitative
nalysis of clopidogrel in bulk and in tablet formulations.
he method was completely validated and showed satis-
actory results for all the method validation parameters
ested; the method is free from interference from the
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other active ingredients and additives used in the for-
mulations. The method showed linearity in the range
10–60 g/mL with a regression coefficient of 0.999. The
recovery is nearly 100%. The RSD was < 0.1%, which
is an added advantage over previous methods. In pre-
vious studies, only single marketed formulations were
assayed, whereas we tested two different formulations.
The method is suitable for use in routine quality control
of clopidogrel in API or pharmaceutical dosage forms.
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